Respiratory
Addressing the complexity of respiratory research
![Pulmonary fibrosis_home page_banner Pulmonary fibrosis_home page_banner](https://icon.widen.net/content/xf96nmlswg/web/Pulmonary%20fibrosis_home%20page_banner.jpg)
Pushing boundaries in idiopathic pulmonary fibrosis clinical research
Idiopathic pulmonary fibrosis (IPF) is a progressive and life-limiting lung disease characterised by scarring (fibrosis) of the lung tissue which primarily affects older adults. The exact cause of the disease is unknown, however, certain risk factors, such as a history of smoking, and genetic predisposition, may increase the likelihood of developing the disease.
![Thumbnail_IPF_blog-doctor-patient Thumbnail_IPF_blog-doctor-patient](https://icon.widen.net/content/gypigxgkjt/web/Thumbnail_IPF_blog-doctor-patient.jpg)
Pushing boundaries in idiopathic pulmonary fibrosis clinical research
The landscape of IPF research is evolving and early-stage biopharmaceutical teams need a new roadmap to success. We offer strategies to meet the challenges to develop new treatments.
![Vaccines-Covid-19_picture_componant Vaccines-Covid-19_picture_componant](https://icon.widen.net/content/awrdloqtul/web/Vaccines-Covid-19_picture_componant.jpg)
Pandemic respiratory vaccine clinical trials: A departure from business as usual
Vaccine trials for respiratory viruses, even in the best of circumstances, present a number of operational challenges for researchers, many of which are exacerbated in the face of a pandemic created by a novel virus. We focus on the corresponding success factors that can keep pandemic respiratory vaccine trials running at optimal speed and efficiency.